Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Transcat, Inc.
TRNS
NASDAQ·Industrials·Industrial - Distribution·Mkt cap $866.0M
$89.03
▼ -3.97%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$50.23 - $94.76
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 4.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Specialized expertise in highly regulated life sciences and FDA-regulated industries with high switching costs
- Proprietary software platform (CalTrak) creating recurring revenue and customer lock-in through integrated workflow management
- Dual-segment business model enabling cross-selling, recurring service revenue, and diversified customer base
- 60+ year operational history and established relationships in mission-critical compliance and quality assurance
Bear Case
2 risks
- Low volatility (beta 0.7).
- High premium - requires strong execution
Growth
Moderate growth ahead
Increasing regulatory compliance requirements in pharmaceutical, biotechnology, and medical device industries
Value
High premium - requires strong execution
Momentum
Hot
+21.7% over 3m
Quality
Stable
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying TRNS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 25, 2026
MAY 26, 2026
Reported EPS of $0.56 vs $0.51 consensus (+9.8% surprise). Revenue of $89.3M vs $89.8M expected (-0.5%).
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+9.8%
Next: May 25, 2026
Revenue trend · last 8Q
—
—
—
+4%
+9%
+16%
+21%
+8%
Q4 24
Q1 24
Q2 24
Q3 24
Q4 25
Q1 25
Q2 25
Q3 25
$70.9M
$66.7M
$67.8M
$67.8M
$77.1M
$77.1M
$82.3M
$73.3M
Margins · last 8Q
Gross
34.1%
Operating
8.1%
Profit
5.0%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
No analyst coverage on file for this stock yet.